ESMO 23: Analysts Keep Faith In Revolution’s Multi-RAS Drug Despite Investor Fright

Revolution Medicines is aiming to go beyond Amgen and Mirati’s first-generation drugs with a multi-RAS targeting therapy - and despite a market sell-off after ESMO, analysts think the company think it is still on track.